Sorrento Therapeutics (SRNE) and SmartPharm Therapeutics have now signed a merger agreement for Sorrento to acquire SmartPharm, a gene-encoded therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases.Shares in Sorrento rose 4% in Thursday’s after-hours trading.As previously announced on July 24, SmartPharm equity holders will receive up to an aggregate of $19.4 million of Sorrento common stock, based on a price per share calculated in accordance with the merger agreement.Sorrento and SmartPharm will also collaborate on research and development to encode and express in vivo Sorrento’s proprietary SARS-CoV-2 neutralizing monoclonal antibodies with SmartPharm’s Gene …read more
Source:: Yahoo Finance
